Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Jisce R. Puik

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0545-1762; OpenAlex author ID A5043747138. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper

Papers 8

  1. 18F-Prostate-Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN-2): a phase I/II study. Co-author DOI 10.1186/s40644-025-00822-y↗
  2. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  3. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13046-024-03090-z↗
  4. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers. Co-author DOI 10.1001/jamanetworkopen.2023.31197↗
  5. hENT1 as a Predictive Biomarker in PDAC-Letter. Co-author DOI 10.1158/1078-0432.ccr-22-3827↗
  6. The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel A… Co-author DOI 10.3390/cancers14020344↗
  7. Novel Strategies to Address Critical Challenges in Pancreatic Cancer. Co-author DOI 10.3390/cancers14174115↗
  8. Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights. Co-author DOI 10.1002/onco.13606↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Geert Kazemier M · 8 shared papers, 2021–2025 · strength 1.43
  2. Elisa Giovannetti · 8 shared papers, 2021–2025 · strength 1.43
  3. Rutger‐Jan Swijnenburg · 4 shared papers, 2022–2025 · strength 0.79
  4. Laura L. Meijer · 4 shared papers, 2022–2024 · strength 0.65
  5. Tessa Y. S. Le Large · 4 shared papers, 2022–2024 · strength 0.65
  6. Lenka N.C. Boyd · 4 shared papers, 2022–2024 · strength 0.65
  7. Hanneke W.M. van Laarhoven · 4 shared papers, 2022–2024 · strength 0.65
  8. Annalisa Comandatore · 3 shared papers, 2023–2024 · strength 0.48
  9. Marc G. Besselink · 3 shared papers, 2023–2024 · strength 0.48
  10. Luca Morelli · 3 shared papers, 2023–2024 · strength 0.48
  11. Adam Enver Frampton · 3 shared papers, 2023–2024 · strength 0.48
  12. Johanna W. Wilmink · 2 shared papers, 2024–2025 · strength 0.41
  13. Ingrid Garajová · 2 shared papers, 2023–2024 · strength 0.32
  14. Joanne Verheij · 1 shared paper, 2025 · strength 0.24
  15. Thomas T. Poels · 1 shared paper, 2025 · strength 0.24
  16. Andrea Mambrini · 1 shared paper, 2024 · strength 0.17
  17. Mahrou Vahabi · 1 shared paper, 2024 · strength 0.16
  18. Benoît Immordino · 1 shared paper, 2024 · strength 0.16
  19. Daniel Liu · 1 shared paper, 2024 · strength 0.16
  20. Jonathan Krell · 1 shared paper, 2024 · strength 0.16
  21. Long R. Jiao · 1 shared paper, 2024 · strength 0.16
  22. Shivan Sivakumar · 1 shared paper, 2024 · strength 0.16
  23. Btissame El Hassouni · 1 shared paper, 2021 · strength 0.16
  24. Alessandro Gregori · 1 shared paper, 2021 · strength 0.16
  25. Dongmei Deng · 1 shared paper, 2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.